Eve H Barlow

This inventor holds 8 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc., Zoetis Belgium S.a. Active years: 2011-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eve H Barlow. Retrieved from https://idiyas.com/inventor/eve-h-barlow

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 6)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 6(Granted Patents)

Location History:

Wellesley, MA (US) (2011 - 2018)
Princeton, MA (US) (2016 - 2018)

Company Filing History:

4 out of 167

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2011-2018

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10125192 - Caninized anti-NGF antibodies and their use (2018-11-13),

2. 10093725 - Anti-NGF antibodies and their use (2018-10-09),

3. 10040852 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2018-08-07),

4. 9605069 - Antibodies against the RGM a protein and uses thereof (2017-03-28),

5. 9505829 - Anti-NGF antibodies and their use (2016-11-29),

6. 9255146 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2016-02-09),

7. 8962803 - Antibodies against the RGM A protein and uses thereof (2015-02-24),

8. 7906120 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) (2011-03-15),

Title: The Innovative Contributions of Eve H Barlow

Introduction

Eve H Barlow is a prominent inventor based in Wellesley, MA, known for her significant contributions to the field of biotechnology. With a total of 8 patents to her name, she has made remarkable advancements in the development of antibodies that target nerve growth factor (NGF). Her work has implications for treating various disorders where NGF activity is detrimental.

Latest Patents

Among her latest patents are "Caninized anti-NGF antibodies and their use" and "Anti-NGF antibodies and their use." These patents encompass NGF binding proteins, specifically focusing on chimeric, CDR grafted, and canonized antibodies. The antibodies described in these patents are useful for detecting NGF and inhibiting its activity in mammals suffering from related disorders.

Career Highlights

Eve has worked with notable companies such as AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of therapeutic antibodies.

Collaborations

Throughout her career, Eve has collaborated with esteemed colleagues, including Mary Leddy and Bernhard K. Mueller. These partnerships have further enhanced her research and innovation in the biotechnology sector.

Conclusion

Eve H Barlow's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments targeting NGF-related disorders.

Profile summary based on public USPTO records.